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SUMMARY
The application of existing methods for constructing optimal dynamic treatment regimes is
limited to cases where investigators are interested in optimizing a utility function over a fixed
period of time (finite horizon). In this manuscript, we develop an inferential procedure based on
temporal difference residuals for optimal dynamic treatment regimes in infinite-horizon settings,
where there is no a priori fixed end of follow-up point. The proposed method can be used to deter-
mine the optimal regime in chronic diseases where patients are monitored and treated throughout
their life. We derive large sample results necessary for conducting inference. We also simulate
a cohort of patients with diabetes to mimic the third wave of the National Health and Nutrition
Examination Survey, and we examine the performance of the proposed method in controlling the
level of hemoglobin A1c. Supplementary materials for this article are available online.
Some key words: Action-value function; Causal inference; Backward induction; Temporal difference residual.
1. INTRODUCTION
A dynamic treatment regime (DTR) is a treatment process that considers patients’ individual
characteristics and their ongoing performance to decide which treatment option to assign. DTRs
can, potentially, reduce side effects and treatment costs, which makes the process attractive for
policy makers. The optimal DTR is the one that, if followed, yields the most favorable outcome
on average. Depending on the context, the DTR is also called an adaptive intervention (Collins
et al., 2004) or adaptive strategy (Lavori & Dawson, 2000).
The goal of this manuscript is to devise a new methodology that can be used to construct the
optimal DTR in infinite-horizon settings (i.e., when the number of decision points is not nec-
essarily fixed for all individuals). The estimation procedure, however, is based on observational
data collected over a fixed period of time that includes many decision points. One potential ap-
plication of our method is to estimate the optimal treatment regime for chronic diseases using
data extracted from an electronic medical record data set during a fixed period of time.
This work was motivated by the National Health and Nutrition Examination Survey
(NHANES), which was designed to assess the health status of adults and children in the United
States. Timbie et al. (2010) simulates a cohort of subjects diagnosed with diabetes that mimics
the third wave of the NHANES and uses this cohort to evaluate the ability of available treat-
ments to control risk factors. Specifically, Timbie and colleagues’ study was designed to manage
the risk factors for vascular complications such as high blood pressure, high cholesterol and high
blood glucose (Grundy et al., 2004; Hunt, 2008). In this manuscript, we simulate a cohort similar
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2 A. ERTEFAIE
to Timbie’s. Our focus is on constructing a DTR for lowering hemoglobin A1c among patients
with diabetes.
One challenge in constructing an optimal regime is avoiding treatments that are optimal in the
short term but do not result in an optimal long-term outcome. To address this challenge, Murphy
(2003) introduced a method based on backward induction (dynamic programming) to estimate
the optimal regime using experimental or observational data. Murphy’s method starts from the
last decision point and finds the treatment option that optimizes the outcome and goes backward
in time to find the best treatment regime for all the decision points (Bather, 2000; Jordan, 2002).
More specifically, backward induction maps the covariate history of each individual to an optimal
regime. Another method was introduced by Robins (2004) using structural nested mean models
(SNMMs). The key notion in Murphy’s and Robins’ methods is that the optimal regime can
be characterized by just modeling the difference between the outcome under different treatment
regimes, rather than the full outcome model. Robins (2004) proposes G-estimation as a tool to
estimate the parameters of SNMMs, while Murphy (2003) uses a least square characterization
method (Moodie et al., 2007).
Q-learning, a reinforcement learning algorithm, is also widely used in constructing the op-
timal regime (Murphy et al., 2006; Zhao et al., 2009; Chakraborty et al., 2010; Nahum-Shani
et al., 2012). Q-learning is an extension of the standard regression method that can be used with
longitudinal data in which treatments vary over time. Goldberg & Kosorok (2011) introduce a
new Q-learning method that can be used when individuals are subject to right censoring. Their
new method creates a pseudo population in which everyone has an equal number of decision
points and they show that the results obtained by the pseudo population can be translated to the
original problem (Zhao et al., 2011; Zhang et al., 2012, 2013). Schulte et al. (2014) provides a
self-contained description of different methods for estimating the optimal treatment regime in
finite horizon settings.
The existing methods in the statistics literature are specifically designed to estimate the optimal
treatment regime that optimizes a utility function over a fixed period of time. However, in this
manuscript our inferential goal is to construct the optimal regime in infinite horizon settings with
data that are collected over a fixed period of time. This requires a methodology that estimates the
Q-function and the optimal decision rule without the time index. We achieve this by developing
an estimating equation that estimates the optimal regime without requiring backward induction
from the last to the first decision point. In order to capture the disease dynamic and the long-term
treatment effects, our dataset should contain a long trajectory of data with many decision points.
The remainder of this manuscript is organized as follows. Section 2 explains the data struc-
ture and presents the proposed method. In Section 3, we develop asymptotic properties of the
method. We conduct a simulation study in Section 4 to examine the performance of our method.
The last section contains some concluding remarks. All the proofs are relegated to an online
supplementary document.
2. CONSTRUCTING THE OPTIMAL REGIME
2·1. Data structure
We study the effect of a time-dependent treatment At on a function of outcome. Our
data set is composed of n i.i.d. trajectories. The ith trajectory is composed of the sequence
(Xi0, Ai0, ..., Ai(T−1), XiT ), where Xit(.) is the set of variables measured at the tth decision
point and Ait is the treatment assigned at that decision point after measuring Xit(.). T is the
maximal number of decision points, and the observed length of trajectories are allowed to be dif-
ferent. At each decision point t, we define a variable Sit as a summary function of the observed
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history (such as time-varying covariates, prior response, baseline covariates and treatment his-
tory) that depends on, at most, the last k time points. We assume that the support of St is the
same for all ts and denote it as S . If a patient dies before the last decision point, say t, we set
St = ∅ (absorbing state). Given St = s, At takes values in As = {0, 1, 2, ...,ms} for all t where
ms <∞, ∀s ∈ S. We set As = ∅ for s = ∅. The treatment and the summary function history
through t are denoted by A¯t and S¯t, respectively. We use lowercase letters to refer to the possible
values of the corresponding capital letter random variable. From this point forward, for simplicity
of notation, we drop the subscript i.
2·2. Potential outcomes
We use a counterfactual or potential outcomes framework to define the causal effect of interest
and to state assumptions. Potential outcomes models were introduced by Neyman (1990) and
Rubin (1978) for time-independent treatment and later extended by Robins (1986, 1987) to assess
the time-dependent treatment effect from experimental and observational longitudinal studies.
Associated with each fixed value of the treatment vector a¯m, we conceptualize a vector of the
potential outcomes S¯m+1(a¯m) = (S2(a1), ..., Sm+1(a¯m)), where St+1(a¯t) is the value of the
summary function at the (t+ 1)th decision point that we would have observed had the individual
been assigned the treatment history a¯t.
In the potential outcomes framework, we make the following assumptions to identify the
causal effect of a dynamic regime.
1. Consistency: St+1(A¯t) = St+1 for each t
2. Sequential randomization: {St+1(a¯t), St+2(a¯t+1), ..., ST (a¯T−1)} |= At|S¯t, A¯t−1 = a¯t−1.
These assumptions link the potential outcome and the observed data (Robins, 1994, 1997).
Assumption 1 means that the potential outcome of a treatment regime corresponds to the actual
outcome if assigned to that regime. Assumption 2 means that within levels of St, treatment
at time t, At, is randomized. Throughout this manuscript, we assume that these identifiability
assumptions hold.
Besides the above assumptions, we assume that the data generating law satisfies the following
assumptions:
A.1 Markovian assumption: Fot each t,
St |= S¯t−2, A¯t−2|St−1, At−1 (1)
At |= S¯t−1, A¯t−1|St (2)
A.2 Time homogeneity: For each s ∈ S and a ∈ As,
p(St+1 ∈ B|St = s,At = a) = p(S′ ∈ B|S = s,A = a),
where S and S′ are the summary functions at the previous and the next time, respectively.
From this point forward, we refer to S as a state variable.
A.3 Positivity assumption: Let pA|S(a|s) be the conditional probability of receiving treatment
a given S = s. For each action a ∈ As and for each possible value s, pA|S(a|s) > 0.
Assumption A.2 means that the conditional distribution of the Ss does not depend on t. A.3
ensures that all treatment options inAs have been assigned to some patients (i.e., for each S = s,
all actions in As are possible). This assumption is also known as an exploration assumption.
Assumptions A.1 and A.2 provide guidance for how to construct the state variable St. The
Markovian assumptions (1) and (2) seem to be unrealistic in many studies of chronic diseases.
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But they are not. This is because, if it is necessary, one can construct the state variable St such
that it includes previous treatments and observed intermediate outcomes. Thus, for example,
(2) does not indicate that decision makers make the next treatment decision taking into account
only the last outcome data, i.e. disregarding the earlier treatments and outcomes, because these
information can be included in the preceding state variable, say St.
In cases where St has to depend on the observed history of the last k time points, assumption
A.2 is satisfied only if we ignore the first k − 1 time points of the observed trajectory of patients.
This is because the support of St is the same only for t ≥ k.
2·3. The likelihood
Under assumptions A.1–3, the distribution of the observed trajectories is composed of the
distribution of the trajectory St given (St−1, At−1), say fS′|S,A, and the density pA|S(a|s). The
likelihood of the observed trajectory {s0, a0, ..., aT−1, sT } is given by
fS(s0)p(a0|s0)
T∏
k=1
fS′|S,A(sk|sk−1, ak−1)
T−1∏
k=1
p(ak|sk). (3)
Expectations with respect to this distribution are denoted by E.
The treatment regime (policy), pi, is a deterministic decision rule where for every s, the output
pi(s) is an action a ∈ As, whereAs is the space of feasible actions (Robins, 2004; Schulte et al.,
2014). The likelihood of the trajectory {s0, a0, ..., aT−1, sT } corresponding with this law is
f(s0)I(a0 = pi(s0))
T∏
k=1
fS′|S,A(sk|sk−1, ak−1)
T−1∏
k=1
I(ak = pi(sk)). (4)
Expectations with respect to this distribution are denoted by Epi. Note the likelihood (4) is not
well-defined and it may be identical to zero unless A.3 holds for each possible value s and
a ∈ As. Note that, the observed trajectory {s0, a0, ..., aT−1, sT } may be truncated by death at
time m. In this case, we have Sm = Sm+1... = ST = ∅, and Am = Am+1... = AT = ∅ and by
definition, for allm′ ≥ m, p(Sm′+1 = ∅|Sm′ = ∅, Am′ = ∅) = 1 and p(Am′ = ∅|Sm′ = ∅) = 1.
2·4. Preliminaries
We define the reward value as a known function of (St−1, At−1, St) at each time t and denote
it by Rt = r(St−1, At−1, St). The reward value is a longitudinal outcome that is coded such that
high values are preferable. We set Rt = 0 if St−1 = ∅.
The action-value function at time t,Qpit (s, a), is defined as an expected value of the cumulative
discounted reward if taking treatment a at state s at time t and following the policy pi afterward.
In other words, Qpit (s, a) quantifies the quality of policy pi when St = s and At = a. Hence,
Qpit (s, a) is defined as Epi
[∑∞
k=1 γ
k−1Rt+k|St = s,At = a
]
, where γ is called a discount fac-
tor, 0 < γ < 1, which is fixed a priori by the researcher. Note that by definition of the reward
function,Qpit (∅, a) = 0. Under the Markovian assumption, the action-value function does not de-
pend on t. Thus we can drop the subscript t and denote it by Qpi(s, a). Note that the action-value
function Qpi(., .) has a finite value when γ < 1 and the rewards are bounded.
The discount factor γ balances the immediate and long-term effect of treatments on the action-
value function. If γ = 0, the objective would be maximizing the immediate reward and ignoring
the consequences of the action on future rewards or outcomes. As γ approaches one, future
rewards become more important. In other words, γ specifies our inferential goal. In Section S4
of the supplementary materials we discuss the effect of the choice of γ on the estimated optimal
regime.
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The action-value function can be written as
Qpi(s, a) = Epi
[ ∞∑
k=1
γk−1Rt+k|St = s,At = a
]
= Epi
[
Rt+1 + γ
∞∑
k=1
γk−1Rt+k+1|St = s,At = a
]
= E
[
Rt+1 + γEpi
{ ∞∑
k=1
γk−1Rt+k+1|St+1, At+1 = pi(St+1)
}
|St = s,At = a
]
= E [Rt+1 + γQ
pi(St+1, pi(St+1))|St = s,At = a] .
The last equation is known as Bellman equation for Qpi(s, a) (Sutton & Barto, 1998; Si, 2004).
The inner expectation quantifies the quality of policy pi at time (t+ 1), in state St+1 and with
treatment pi(St+1). Taking treatment pi(St+1) at time (t+ 1) ensures treatment policy pi is fol-
lowed in the interval (t, t+ 1].
Our goal is to construct a treatment policy that, if implemented, would lead to an optimal
action-value function for each pair (s, a). Accordingly, the optimal action-value function can be
defined as
Q∗(s, a) = max
pi
Epi
[ ∞∑
k=1
γk−1Rt+k|St = s,At = a
]
= max
pi
E
[
Rt+1 + γEpi
{ ∞∑
k=1
γk−1Rt+k+1|St+1, At+1 = a∗
}
|St = s,At = a
]
= E
[
Rt+1 + γmax
pi
Epi
{ ∞∑
k=1
γk−1Rt+k+1|St+1, At+1 = a∗
}
|St = s,At = a
]
= E [Rt+1 + γQ
∗(St+1, a∗)|St = s,At = a] ,
where a∗ ∈ arg maxaQ∗(St+1, a). Taking treatment a∗ at time (t+ 1) ensures that we are tak-
ing an optimal treatment in the interval (t, t+ 1]. The last equality follows from the definition of
Q∗(s, a) and can also be written as
Q∗(s, a) = E
[
Rt+1 + γmax
a′
Q∗(St+1, a′)|St = s,At = a
]
. (5)
Note that the only distribution involved in the E is fS′|S,A. Denote any policy pi∗ for which
Q∗(s, a) = Epi∗
[ ∞∑
k=1
γk−1Rt+k|St = s,At = a
]
as an optimal policy. So, for state s, we can define the optimal policy as pi∗(s) =
arg maxaQ
∗(s, a) and the optimal value function as V ∗(s) = Q∗(s, pi∗(s)).
The action-value function Q∗(s, a) can be estimated by turning the recurrence relation (5)
into an update rule that relies on estimating the conditional density fS′|S,A. However, when the
cardinality of (S,A) and the dimension of St are large, estimation of the conditional densities is
infeasible. We refer to this method as the classical approach and explain it in Section 4 (Simester
et al., 2006; Mannor et al., 2007). One way to overcome this limitation is to use a linear function
approximation for Q∗(s, a), which is discussed in the following subsection.
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2·5. The proposed estimating equation
The optimal action-value function (5) is unknown and needs to be estimated in order to con-
struct the optimal regime. Suppose theQ∗(., .) function can be represented using a linear function
of parameters θ0,
Q∗(s, a) = θ>0 ϕ(s, a),
where θ0 is the parameter vector of p dimension and ϕ(s, a) can be any vector of features sum-
marizing the state and treatment pair (s, a) (Sutton et al., 2009a,b; Maei et al., 2010). Features
are constructed such that ϕ(∅, a) = 0. Accordingly, we define the optimal dynamic treatment
regime pi∗(s) as arg maxa θ>0 ϕ(s, a).
Now we discuss how to estimate the unknown vector of parameters θ0. First, we define an
error term and then we construct an estimating equation. In view of the Bellman equation (5),
for each t, we have
E
[
Rt+1 + γmax
a′
Q∗(St+1, a′)−Q∗(St, At)|St = s,At = a
]
= 0. (6)
Thus, the error term at time (t+1) in the linear setting can be defined as δt+1(θ) = Rt+1 +
γmaxa′ [θ
>ϕ(St+1, a′)]− θ>ϕ(St, At), which is known as temporal difference error in com-
puter science literature. In order to account for the influence of the feature function ϕ(S,A) in
the estimation of the θs, we multiply δ(θ) by ϕ(S,A) and define θ0 as a value of θ such that
D(θ) = E
[
T−1∑
t=0
δt+1(θ)ϕ(St, At)
>
]
= 0. (7)
The expectation in the above equation depends on the transition densities fS′|S,A and pA|S . Note
that as in (6),
D(θ0) = E
[
T−1∑
t=0
{Rt+1 + γmax
a
[θ>0 ϕ(St+1, a)]− θ>0 ϕ(St, At)}ϕ(St, At)>
]
=
T−1∑
t=0
E
[
{Rt+1 + γmax
a
[θ>0 ϕ(St+1, a)]− θ>0 ϕ(St, At)}ϕ(St, At)>
]
= 0.
Hence, given the observed data, an unbiased estimating equation for θ can be defined as
Dˆ(θ) = Pn
[
T−1∑
t=0
δt+1(θ)ϕ(St, At)
>
]
= 0, (8)
where Pn is the empirical average.
3. CALCULATION
In practice, sometimes there is no θˆ that solves the system of equations (8), and sometimes the
solution is not unique. One way to deal with this is to take an approach similar to the least square
technique and define θˆ as a minimizer of an objective function. As in (7), a simple objective
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function can be defined as
E
[
T−1∑
t=0
δt+1(θ)ϕ(St, At)
>
]
E
[
T−1∑
t=0
δt+1(θ)ϕ(St, At)
>
]>
(Sutton et al., 2009b). The objective function used in this manuscript is the above function
weighted by the inverse of the feature covariance matrix and defined as
M(θ) = D(θ)W−1D(θ)>, (9)
where W = E
[∑T−1
t=0 ϕ(St, At)ϕ(St, At)
>
]
is a full-rank matrix. The weight W−1 improves
the performance of the proposed stochastic minimization algorithm in Section S1 of the supple-
mentary materials. The function M(θ) is a generalization of the objective function presented in
Maei et al. (2010).
The objective function M(θ) can be estimated using the observed (st, at) by
Mˆ(θ) = Dˆ(θ)Wˆ−1Dˆ(θ)>, (10)
where Dˆ(θ) = Pn
[∑T−1
t=0 δt+1(θ)ϕ(St, At)
>
]
and Wˆ = Pn
[∑T−1
t=0 ϕ(St, At)ϕ(St, At)
>
]
.
Define θˆ ∈ arg minθ Mˆ(θ). Then, the estimated optimal dynamic treatment regime is pˆi(s) =
arg maxa θˆ
>ϕ(s, a). By law of large numbers, the estimator Mˆ(θ) is a consistent estimator of
M(θ).
The following theorem presents the consistency and asymptotic normality of estimator θˆ where
the asymptotic normality result relies on the uniqueness of the optimal treatment at each decision
point. This allows investigators to test the significance of variables for use in this sequential
decision making problem. Assumptions A.4− 8 required in this section are listed in Appendix
3.
THEOREM 1. (Consistency and asymptotic normality) For a map θ →M(θ), defined in (9),
under assumptions A.4− 7, any sequence of estimators θˆ with Mˆ(θˆ) ≤ Mˆ(θ0) + op(1) satisfies
the following statements:
I. For small enough γ,
√
n(θˆ − θ0) = Op(1).
II. Under A.8,
√
n(θˆ − θ0)→d N(0,Γ>ΣΓ), where
Σ = E
{∑
t
δt+1ϕ(St, At)
>
}>{∑
t
δt+1ϕ(St, At)
>
} ,
Γ =
[
I − γ W−1E
(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)]>
W + γ2E(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)
W−1E
(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)>
−2γE
(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)>−1 ,
where I is an identity matrix and δt+1 = [Rt+1 + γmaxa θ>0 ϕ(St+1, a)− θ>0 ϕ(St, At)].
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Proof. See the supplementary material. 
In Section S3 of the supplementary materials, we show that under assumption A.8,
√
n(θˆ −
θ0) = Op(1) for any γ ∈ (0, 1). The asymptotic variance Γ>ΣΓ may be estimated consistently
by replacing the expectations with expectations with respect to the empirical measure and re-
placing θ0 with its estimate θˆ.
The objective functionM(θ) is a non-convex and non-differentiable function of θ, which com-
plicates the estimation process. Standard optimization techniques often fail to find the global
minimizer of this function. In Section S1 of the supplementary materials, we present an incre-
mental approach, which is a generalization of greedy gradient Q-learning (GGQ), an iterative
stochastic minimization algorithm, introduced by Maei et al. (2010) as a tool to minimize M(θ).
Hence, from this point forward, we refer to our proposed method as GGQ.
4. SIMULATION STUDY
We simulate a cohort of patients with diabetes and focus on constructing a dynamic treatment
regime for maintaining the hemoglobin A1c below 7%. The A1c-lowering treatments that we
consider in this manuscript are similar to those of Timbie et al. (2010) and include metformin,
sulfonylurea, glitazone, and insulin. We used treatment discontinuation rates to measure patients’
intolerance to treatment and reflect both the side effects and burdens of treatment. The treatment
efficacies and discontinuation rates are extracted from Kahn et al. (2006) and Timbie et al. (2010).
We assume that patients who discontinue a treatment do not drop out but just take the next
available treatment. These simulated data mimic the third wave of NHANES.
In Section 4.3, we compare the performance of our proposed approach with the classical
approach using a simulated dataset and then in Section 4.4 we perform a Monte Carlo study to
examine the asymptotic results.
4·1. Overview of the simulation
Our study consists of 20 decision points, and the time between each decision point is 3 months.
Eligible individuals start with metformin and augment with treatments sulfonylurea, glitazone,
and insulin through the follow-up. At each decision point, there are two treatment options: 1)
augment the treatment 2) continue the treatment received at the previous decision point. The
discontinuation variable D is generated from a Bernoulli distribution given at the last aug-
mented treatment. NATt is the number of augmented treatments by the end of interval t where
NATt ∈ {0, 1, 2, 3, 4}. The variable At is the augmented treatment at time t. As soon as a treat-
ment is augmented the variable NAT increases by one, whether or not the treatment will be
discontinued. The death indicator variable Ct at time t is generated as a function of previous
observed covariates.
4·2. Generative model
Here are the steps we take to generate the dataset:r Baseline variables: Variables (BP0,Weight0, A1c0) are generated from a multivariate nor-
mal distribution with mean (13,160,9.4) and the covariance matrix diag(1, 1, 1), where BP is
the systolic blood pressure. Also, NAT0 = D0 = C0 = 0.r Assigned treatment at time t: Given the state variable NATt, the sets of available treat-
ments are ANATt=0 = {0,Metformin}, ANATt=1 = {0, Sulfonylurea}, ANATt=2 =
{0, Glitazone}, ANATt=3 = {0, Insulin}, and ANATt=4 = {0}, where 0 means continue
with the treatment received at the previous decision point. Although the ideal A1c level is
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below 7%, Timbie et al. (2010) raises concern about the feasibility and polypharmacy bur-
den needed for treating patients whose 7 < A1c < 8. Our simulation study investigates the
optimal treatment regime for these patients. More specifically,
– if A1ct < 7, the treatment is not augmented because A1c is under control and NATt =
NATt−1.
– if A1ct > 8 and NATt−1 < 4, the treatment is augmented with the next available treat-
ment. Hence, NATt = NATt−1 + 1. Note that these are patients whose A1c is too high.
Thus, the only option is augmenting their treatment.
– If 7 < A1ct < 8 and NATt−1 < 4, then a binary variable Zt is generated from Zt ∼
Ber
(
exp[−0.2A1ct−1+0.5NATt−1+0.5Dt−1]
1+exp[−0.2A1ct−1+0.5NATt−1+0.5Dt−1]
)
, where Dt denotes the discontinuation indi-
cator. Zt = 1 implies that the patient continues with the same treatment as time t− 1 and
we set At = 0 (NATt = NATt−1), while Zt = 0 implies that the patient takes the next
available treatment (treatment is augmented) and we set NATt = NATt−1 + 1. For exam-
ple, if 7 < A1ct < 8 and NATt−1 = 3, a patient can be assigned to either augmenting the
treatment taken at time t− 1 with At = insulin or continuing with the same treatment as
time t− 1 (At = 0), depending on the generated variable Zt.
Note: When Zt = 1, no new treatment is added. Hence, E[A1ct|Zt = 1, A1ct−1] =
E[A1ct|At = 0, A1ct−1] = A1ct−1.r Treatment discontinuation indicator at time t: A binary variable Dt is generated from a
Bernoulli distribution given the last augmented treatment. For all t, the treatment discontinu-
ation rates are p(Dt|At−1 = metformin) = p(Dt|At−1 = sulfonylurea) = p(Dt|At−1 =
glitazone) = 0.20, and p(Dt|At−1 = insulin) = 0.35.
Note: We assume no treatment discontinuation for patients who are taking the same treatment
at time t as at time t− 1 (i.e., p[Dt = 1|At−1 = 0] = 0).r Intermediate outcome A1c at time t: To avoid variance inflation through time, we use the fol-
lowing generative model forA1c at time t,A1ct =
A1ct−1−µt−1+√
(1+σ2 )
+ µt, where  ∼ N(0, σ =
0.5) and
µt = E[A1ct|A1ct−1, NATt−1, At, Dt] =
{
µt−1(1− τAt) if A1ct−1 > 7, NATt−1 < 4, At 6= 0, Dt 6= 1,
µt−1 o.w.
with τAt being the treatment effect of the augmented treatment At. The treatment effects of
metformin, sulfonylurea, glitazone∗ and insulin are 0.14, 0.20, 0.02, and 0.14, respectively.
Note that the treatment effects are reported as a percentage reduction in A1c. The treatment
effect of glitazone is listed as 0.12 in Timbie et al. (2010), which is similar to metformin.
However, in order to study the effect of the treatment discontinuation on the optimal regime,
we set its treatment effect to 0.02 and, from now on, denote it by glitazone∗.r Time-varying variables at time t: BPt = (BPt−1 + )/(√1 + σ2 ) and Weightt =
(Weightt−1 + )/(
√
1 + σ2 ).r Death indicator at time t: A binary variable Ct is generated from a Bernoulli distribution with
probability
exp{−10+0.08I(A1ct−1>7)A1c2t−1+0.5NATt−1}
1+exp{−10+0.08I(A1ct−1>7)A1c2t−1+0.5NATt−1}
. Ct = 1 is the indicator of death.r Reward function at time t: In order to be able to find an optimal treatment regime, we need
an operational definition of controlled A1c. Hence, we define the following reward function
at time t as a function of A1ct, Dt and Ct,
– Rt = 1 if A1ct < 7, -2 if 7 < A1ct&Dt = 1, -10 if Ct = 1 and zero otherwise.
This reward structure helps us to identify treatments whose discontinuation rate outweighs
their efficacy while reducing the chance of death.
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Note that the state space at time t includes St = (NATt, Dt, A1ct, BPt,Weightt). However,
the Markov property holds with (NATt, Dt, A1ct), and variables BP and Weight are noise
variables. In order to satisfy assumptionA.2, we ignored the first four time points in the observed
trajectory of each patient.
4·3. Analysis of a simulated dataset
We generate two datasets of sizes 2,000 and 5,000 and compare the quality of the estimated
optimal treatment policy using the proposed GGQ and the classical approach. The latter, also
known as action-value iteration method, turns the recurrence relation of (5) into an update rule
as
Q∗k+1(s, a) = E
[
r(s, a, S′) + γmax
a′
Q∗k(S
′, a′)|S = s,A = a
]
=
∑
s′
PS′|S,A(s′|s, a)[r(s, a, S′) + γmax
a′
Q∗k(s, a)],
where r() is the reward function. This procedure can be summarized as
1. set Q∗1(s, a) = 0 for all (s, a) ∈ (S,As)
2. for each (s, a) ∈ (S,As), q ← Q∗k(s, a)
3. Q∗k+1(s, a)←
∑
s′ PS′|S,A(s
′|s, a)[r(s, a, S′) + γmaxa′ Q∗k(s′, a′)]
4. repeat 2 and 3 until max∀s,a |Q∗k+1(s, a)− q| <  where  is a small positive value
5. for each s, pˆi(s) = arg maxsQ∗k+1(s, a).
The above 5-step procedure is similar to the one presented in Chapter 4 of Sutton & Barto
(1998). Note that the classical approach requires estimation of the transition probabilities
PS′|S,A, which limits its usage to cases where state and action space is small. We catego-
rize the continuous variables (BP,Weight, A1c) and estimate PS′|S,A nonparametrically. The
variables (BP,Weight) are categorized based on the percentiles (30, 80) and denoted as
(Cat.BP,Cat.Weight). The categorized A1c (Cat.A1c) is formed by breaking the variable
A1c on (−∞, 7, 7.2, 7.5, 7.7, 8, 9,+∞). Hence the state variable used in the classical approach is
SClasst = (NATt, Dt, Cat.BP,Cat.Weight, Cat.A1c). Note that Cat.A1c ∈ {2, 3, 4, 5} cor-
responded to 7 < A1c < 8.
Unlike the classical approach, the optimal treatment policy using our proposed GGQ method
utilizes the continuous state variable St = (NATt, Dt, A1ct, BPt,Weightt). In our example,
we parametrize the optimal action value function Q∗(s, a) using a 72-dimensional vector of
parameters and construct the features ϕ(s, a) using radial basis functions (Gaussian kernels).
See Appendix 2 for more details. To specify the step sizes of the stochastic minimization al-
gorithm, first we select two functions that satisfy the conditions P.1− 4 listed in Appendix 1
and multiply them by v ∈ (0, 1). Then we run the algorithm for different values of v and se-
lect the one that minimizes the objective function. In this simulation study we set the step sizes
αk = ν/(k log(k)) and βk = ν/k where ν is set to 0.05. Section S5 in the supplementary mate-
rials discusses the effect of the choice of tuning parameters on the estimated optimal regime.
True optimal policy. As the sample size increases, the optimal action-value function esti-
mated using the classical approach converges to the true optimal action-value function. Hence,
for the purpose of finding the true optimal policy, we generate a large dataset of size 500,000 and
estimate transition probabilities PS′|S,A using a nonparametric approach, where S is the oracle
state (NATt, Dt, Cat.A1ct). Then by the 5-step procedure (classical approach), the true optimal
policy is approximated and set as our benchmark.
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Fig. 1: Simulation: Estimated optimal treatment (op.txt) for different states. The shaded bar rep-
resents the evidence in the simulated data for each of the treatment choices as labeled in the
legend. The upper and lower horizontal axes are the discontinuation indicator and the catego-
rized A1c (Cat.A1c), respectively. The vertical axes on the right and left hand side give NAT
and the percentage of time that the treatment choices are selected as the optimal choice.
Figure 1 depicts the true and estimated optimal treatment for each discretized oracle state
(NATt, Dt, Cat.A1ct) using the GGQ and classical approaches. As in this example, we set the
discount factor γ to 0.6. Note that the estimated optimal policy using classical and GGQ methods
is based on the states SClasst and St, respectively. However, in Figure 1, we averaged it over the
noise variables (BP,Weight) and, for comparability, we report the results on the discretized
oracle state. The vertical axis on the left hand side is the percentage of time that the treatment
choices are selected as optimal. The left vertical and both horizontal axes represent the elements
of the state (NAT,D,Cat.A1c), respectively. This plot shows that the proposed GGQ method
outperforms the classical approach for moderate sample sizes.
More specifically, the estimated optimal policy using GGQ (pˆiGGQ) recommends not augment-
ing the third (glitazone∗) and fourth (insulin) treatments (the left plots). This makes sense since
glitazone∗ has a small treatment effect (0.02) and insulin has high discontinuation rate (0.35) that
outweighs its efficacy. However, the estimated optimal policy using a classical approach (pˆiClass)
recommends augmenting these treatments by some positive probabilities. Specifically, pˆiClass
augments insulin about 50% of the time when D = 1 and Cat.A1c ∈ {2, 3, 4}.
Figure 2 presents the difference between the values of the estimated optimal policies pˆiGGQ and
pˆiClass. The values are calculated using the Monte Carlo method, where the value of a treatment
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Fig. 2: Simulation: Monte Carlo approximation of the difference between value functions.
V piGGQ and V piClass are the value functions corresponding to the classical and GGQ approaches.
The vertical axis represents the triplets of states in the order of (NAT,D,Cat.A1c).
policy pi, for each state s, is defined as V pi(s) = Epi
[∑∞
k=1 γ
k−1Rt+k|St = s,At = pi(s)
]
. For
both sample sizes and all of the states, the value of pˆiGGQ is higher than the value of pˆiClass. This
indicates that the estimated optimal policy pˆiGGQ has better quality.
Our simulation result is consistent with Timbie et al. (2010), and suggests that we should not
always augment the treatment when 7 < A1c < 8. In other words, depending on the treatment
already taken, sometimes we should consider not augmenting the treatment to avoid side effects.
4·4. Monte Carlo studies
We generate 500 datasets each of sizes 2,000 and 5,000 to examine the asymptotic behavior
of the proposed method. Figure 3 shows the confidence intervals of θ, where the standard er-
rors are estimated using the variance formula presented in Theorem 1. The dark circles are the
average of the 500 θˆs and asterisks are the true parameter values approximated using a Monte
Carlo study with n = 10, 000. These confidence intervals may be used to identify the parts of
the feature function that should be kept in the decision rule and may be used as a feature selec-
tion tool. Another important use of the asymptotic results in Theorem 1 is to investigate whether
there is a significant difference between treatment options. Specifically, one may build the confi-
dence interval for the difference between the estimated optimal action-value function for different
treatment options (augment vs. continue) and check whether it contains zero (while adjusting for
Type-I error rate for more than two treatment options). In Figure 4, we constructed and evaluated
the quality of these 95% confidence intervals for Q∗(s, augment)−Q∗(s, 0), given each state
variable for n = 2000. The results for n = 5000 is similar and omitted due to space limitations.
These results confirm the accuracy of our variance estimator in Theorem 1.
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Fig. 3: Simulation: Plot of the 95% confidence intervals of θ.
5. DISCUSSION
We have proposed a new method that can be used to form optimal dynamic treatment regimes
in infinite-horizon settings (i.e., there is no a priori fixed end of follow up), while our data were
collected over a fixed period of time with many decision points. We have assumed that the value
of the optimal regime can be presented using a linear function of parameters, and we developed
an estimating procedure based on temporal difference residuals to estimate the parameters of this
function. We developed the asymptotic properties of the estimated parameters and evaluated the
proposed method using simulation studies.
This work raises a number of interesting issues. We have derived the asymptotic distribution
of the estimators under some assumptions. One important practical problem is to provide a valid
inference when the optimal treatment is not unique for some states, (i.e., assumption A.8 is
violated). This may lead to non-regular estimators and inflate the Type-I error rate (Bickel et al.,
1993). Among others, Robins (2004) and Laber et al. (2010) proposed solutions to this issue.
However, the existing methods may not be directly applied to our method and require major
modifications. The second issue is how to construct the feature functions. In this manuscript, we
used the radial basis functions (Moody & Darken, 1989; Poggio & Girosi, 1990). One simple
method is to try different feature functions (ϕ) and select the one that minimizes the function
f(ϕ) = minθM(θ) (Parr et al., 2008). Alternatively, one may use support vector regression to
approximate the action-value function (Vapnik et al., 1997; Tang & Kosorok, 2012).
The proposed method can be used in settings where the time between decision points is fixed,
say 3 months. This assumption often holds (approximately) for some chronic diseases such as
diabetes, cyclic fibrosis and asthma. It would, however, be of interest to extend the method to
cases with a random decision point (clinic visits). Usually, the random time between decision
points happens either when doctors decide to schedule the next visit sooner or later than the
prespecified time or when patients request an appointment due to, for example, side effects or
acute symptoms. The former is easier to deal with because we have the covariates required to
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Fig. 4: Simulation: The confidence intervals of the difference between the estimated optimal
action-value function when the treatment is augmented and continued (i.e., Qˆ∗(s, augment)−
Qˆ∗(s, 0)). The number on each confidence interval represents the coverage of that interval. The
vertical axis represents the triplets of states in the order of (NAT,D,Cat.A1c).
model the visit process. The latter, however, is more difficult and results in non-ignorable missing
data because we do not have information about those patients who did not show up. Robins et al.
(2008) discusses the issue of the random visit process in detail.
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SUPPLEMENTARY MATERIAL
Supplementary material available at Biometrika online includes the stochastic minimization
algorithm and proof of Theorem 1. It also discusses the effect of the discount factor and tuning
parameters of the stochastic minimization algorithm on the estimated optimal treatment regime.
APPENDIX 1: TUNING PARAMETERS
The tuning parameters αk and βk in the GGQ algorithm need to satisfy the following assumptions
(Maei et al., 2010):
P.1 αk, βk ∀k and are deterministic.
P.2
∑∞
k=0 αk =
∑∞
k=0 βk =∞.
P.3
∑∞
k=0(α
2
k + β
2
k) <∞.
P.4 αk/βk → 0.
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APPENDIX 2: FEATURE FUNCTIONS
The feature functions are constructed using the radial basis functions and
ϕ(s, a) = I(s 6= ∅)(ϕ1(s, a), ϕ2(s, a), ϕ3(s, a), ϕ4(s, a), ϕ5(s, a), ϕ6(s, a), ϕ7(s, a), ϕ8(s, a), ϕ9(s, a)),
where
ϕ1(s, a) = I(A = 0, NAT = 0)(1, exp[−h(A1c− q11)2], exp[−h(A1c− q12)2], φ(BP ), φ(Weight))
ϕ2(s, a) = I(A = 0, NAT = 1)(1, exp[−h(A1c− q21)2], exp[−h(A1c− q22)2], exp[−h(A1c− 8.0)2],
d, φ(BP ), φ(Weight))
ϕ3(s, a) = I(A = 0, NAT = 2)(1, exp[−h(A1c− q31)2], exp[−h(A1c− q33)2], d, φ(BP ), φ(Weight))
ϕ4(s, a) = I(A = 0, NAT = 3)(1, exp[−h(A1c− q41)2], exp[−h(A1c− q42)2, exp[−h(A1c− 8.5)2],
d, φ(BP ), φ(Weight))
ϕ5(s, a) = I(A = 0, NAT = 4)(1, exp[−h(A1c− q51)2], exp[−h(A1c− q52)2, exp[−h(A1c− 8.0)2],
d, φ(BP ), φ(Weight))
ϕ6(s, a) = I(A = 1, NAT = 0)(1, exp[−h(A1c− 6.5)2], exp[−h(A1c− 7.5)2], φ(BP ), φ(Weight))
ϕ7(s, a) = I(A = 2, NAT = 1)(1, exp[−h(A1c− 6.5)2], exp[−h(A1c− q71)2], exp[−h(A1c− q73)2]
d, φ(BP ), φ(Weight))
ϕ8(s, a) = I(A = 3, NAT = 2)(1, exp[−h(A1c− q82)2], exp[−h(A1c− 8.5)2], d, φ(BP ), φ(Weight))
ϕ9(s, a) = I(A = 4, NAT = 3)(1, exp[−h(A1c− 6.5)2], exp[−h(A1c− q92)2, exp[−h(A1c− 8.5)2],
d, φ(BP ), φ(Weight)),
where φ(BP ) = (exp[−h(BP − qb1)2], exp[−h(BP − qb3)2]) and φ(Weight) = (exp[−h(Weight−
qw1)
2], exp[−h(Weight− qw3)2]). h is a positive constant and q.j is the observed jth quantile of the
corresponding variable. For example, q11 and q12 are the first and second quantiles of A1c given A = 0
and NAT = 0. Similarly, qb1 and qb3 are the first and third quantiles of BP . Note that, in our generative
model, BP and Weight are independent of A and NAT .
Remark 1. Number of quantiles used in each ϕk and φ(.) is a bias-variance trade-off such that increas-
ing the number of quantiles decreases the bias but increases the variance of the estimated parameters.
Similarly, decreasing the value of h may decrease the bias but increase the variance of the estimators. In
our simulation, we set h = 0.5.
APPENDIX 3: ASSUMPTIONS
In addition to assumptions A.1-3, the following assumptions are required for large sample properties of
our estimator.
A.4 θ>0 ϕ(., .) is the optimal Q-function.
A.5 E
[∑T−1
t=0 ‖ϕ(St, At)‖2‖ϕ(St, a)‖2
]
<∞, for any a ∈ A.
A.6 The matrix W is of full rank.
A.7 E
[∑T−1
t=0
{
γI|pi∗(St+1)|=1ϕ(St+1, pi
∗(St+1))− ϕ(St, At)
}
ϕ(St, At)
>
]
is of full rank where
pi∗(St+1) = arg maxa θ>0 ϕ(St+1, a) and |.| is the cardinal of a set.
A.8 The optimal treatment is unique at each decision point.
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Web-based Supplementary Materials for
“Constructing Dynamic Treatment Regimes in Infinite-Horizon Settings”
S1. THE STOCHASTIC MINIMIZATION ALGORITHM
We base our minimization procedure on the (approximate) gradient descent approach, in which sub-
gradients are defined as Frechet sub-gradients of the objective function M(θ). Following Maei et al.
(2010) and under under assumptions A.1-8, the algorithm converges to the minimizer of our objective
function.
The sub-gradient ∂M(θ) of M(θ) with respect to θ is
∂M(θ) = −E
[∑
t
δt+1(θ)ϕ(st, at)
>
]
+ γE
[∑
t
ϕ(st+1, pi
∗(st+1))ϕ(st, at)>
]
$,
where $ = E[
∑
t ϕ(st, at)ϕ(st, at)
>]−1E[
∑
t δt+1(θ)ϕ(st, at)
>]. Using the weight-doubling trick in-
troduced by Sutton et al. (2009b), we summarize the steps toward minimizing the objective function
M(θ) as follows:
1. Set initial values for the p dimensional vectors of θ and $. Using grid search, the initial value
θ1 can be set as the one that minimizes the objective function and the initial value w1 =
Pn[
∑
t ϕ(st, at)ϕ(st, at)
>]−1Pn[
∑
t δt+1(θ0)ϕ(st, at)
>].
2. Start from the first individual’s trajectory and obtain θk+1 from the following iterative equations:
θk+1 = θk + αkν
∑
t
[
δt+1(θk)ϕ(st, at)− γ{$>k ϕ(st, at)}ϕ(st+1, pi∗θk(st+1))>
]
(C1)
$k+1 = $k + βkν
∑
t
[
δt+1(θk)− {ϕ(st, at)>$t}>
]
ϕ(st, at)
>, (C2)
where αk, βk and ν are tuning parameters (step sizes) and pi∗θk(.) is the optimal policy estimated as a
function of θk.
3. Use step 2 to continue updating the parameters to the last individual.
4. Continue steps 2 and 3 until ‖θk+1 − θk‖2 < c where c is a constant.
The tuning parameters (step sizes) αk and βk need to satisfy assumptions P.1-P.4 in Appendix A. The
parameter ν tunes the step sizes and lies in the interval (0,1). Our simulation studies show that the best
choice of ν would be close to 1T , where T is the maximal length of the trajectories in our data. See our
discussion in Section S5.
S2. LEMMA
LEMMA 1. Let {ai}K1 and {bi}K1 be two sets of elements, then
I. lim‖b‖→0
max1≤i≤K [ai+bi]−maxi∈pi∗ [ai+bi]
‖b‖ = 0;
II. max1≤i≤K [ai + bi]−maxi∈pi∗ [ai + bi] is non-negative and bounded above by
max
i/∈pi∗
bi −max
i∈pi∗
bi ≤ max
1≤i≤K
bi −max
i∈pi∗
bi
where pi∗ = arg max1≤i≤K ai.
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Proof. Part I. Since the set pi∗ is a subset of 1 ≤ i ≤ K, we have
0 ≤ max1≤i≤K [ai + bi]−maxi∈pi∗ [ai + bi]‖b‖
= max
1≤i≤K
[
ai − ai∗ + bi −max
i∈pi∗
bi
]
1
‖b‖ , ∀i
∗ ∈ pi∗
= max
[
max
i∈pi∗
{bi −max
i∈pi∗
bi},max
i/∈pi∗
{ai − ai∗ + bi −max
i∈pi∗
bi}
]
1
‖b‖
= max
[
0,max
i/∈pi∗
{
ai − ai∗
‖b‖ +
bi −maxi∈pi∗ bi
‖b‖
}]
≤ max
[
0,max
i/∈pi∗
{
ai − ai∗
‖b‖ +
2|max1≤i≤K bi|
‖b‖
}]
Since ai−ai∗‖b‖ → −∞ as ‖b‖ → 0 and |maxi∈pi bi|‖b‖ ≤ 1, part I is proved. Part II can be proved similarly.
S3. PROOF OF THEOREM 1
We first show that the objective function M(θ) is continuous. Then using the results of Lemma 1, we
show thatM(θ) satisfies the two required conditions of Theorem 3.2.1 in Van Der Vaart & Wellner (1996),
which completes the proof of consistency. To prove the asymptotic normality, under the additional as-
sumption A.8, we define a function V (b) such that
√
n(θˆ − θ0)→d arg minb V (b), where arg minb V (b)
is normally distributed.
First, we show that the function M(θ) is continuous by proving the continuity of D(θ) around θ = θ0.
Since
‖D(θ)−D(θ0)‖ = ‖
T−1∑
t=0
E
[
{max
a
[θ>ϕ(St+1, a)]−max
a
[θ>0 ϕ(St+1, a)]
−θ>ϕ(St, At) + θ>0 ϕ(St, At)}ϕ(St, At)>
] ‖,
by the Cauchy-Schwartz inequality and the fact that |maxa f(a)−maxa g(a)| ≤ maxa |f(a)− g(a)|,
we have
E
[
max
a
[θ>ϕ(St+1, a)]−max
a
[θ>0 ϕ(St+1, a)]
]
≤ ||θ − θ0||E
[∑
a
‖ϕ(St+1, a)‖
]
,
which under assumption A.4 implies the continuity of D(θ) around θ = θ0.
Part I (Consistency). We show that M(θ) satisfies the two conditions listed in Theorem 3.2.1 Van Der
Vaart and Wellner (1996). For the first condition, we need to show that for some  > 0 and c > 0 with
||θ − θ0|| < ,
D(θ0)W
−1D(θ0)> −D(θ)W−1D(θ)> ≤ −c||θ − θ0||2,
and since D(θ0) = 0,
D(θ)W−1D(θ)> ≥ c||θ − θ0||2. (C3)
The left hand side of the above inequality can be written as
D(θ)W−1D(θ)> = [D(θ)−D(θ0)− D˙θ0(θ − θ0)]W−1[D(θ)−D(θ0)− D˙θ0(θ − θ0)]>
+ D˙θ0(θ − θ0)W−1D˙θ0(θ − θ0)> + 2D˙θ0(θ − θ0)W−1[D(θ)−D(θ0)− D˙θ0(θ − θ0)]>,
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where
D˙θ0(b) = E
[
T−1∑
t=0
{γ max
a∈pi∗(St+1)
b>ϕ(St+1, a)− b>ϕ(St, At)}ϕ(St, At)>
]
,
and pi∗(St+1) = arg maxa θ>0 ϕ(St+1, a). Note that pi
∗(St+1) may be a set of actions. Now, we show that
‖D(θ)−D(θ0)− D˙θ0(θ − θ0)‖ = o(‖θ − θ0‖).
‖D(θ)−D(θ0)− D˙θ0(θ − θ0)‖
‖θ − θ0‖ =
γ
||θ − θ0||
∥∥∥∥∥E
[
T−1∑
t=0
{
max
a
(θ0 + b||θ − θ0||)>ϕ(St+1, a)− max
a∈pi∗(St+1)
θ>0 ϕ(St+1, a)
− max
a∈pi∗(St+1)
b>ϕ(St+1, a)‖θ − θ0‖
}
ϕ(St, At)
>
]∥∥∥∥ ,
where b = (θ − θ0)/‖θ − θ0‖. Then, since ∀a, a′ ∈ pi∗(St+1), we have θ>0 ϕ(St+1, a) = θ>0 ϕ(St+1, a′).
Thus the following equality holds:
max
a∈pi∗(St+1)
θ>0 ϕ(St+1, a) + max
a∈pi∗(St+1)
(θ − θ0)>ϕ(St+1, a) = max
a∈pi∗(St+1)
θ>ϕ(St+1, a).
Thus,
||D(θ)−D(θ0)− D˙θ0(θ − θ0)||
||θ − θ0‖ =
γ
||θ − θ0||
∥∥∥∥∥E
[
T−1∑
t=0
{
max
a
(θ0 + b||θ − θ0||)>ϕ(St+1, a)− max
a∈pi∗(St+1)
(θ0 + b‖θ − θ0‖)>ϕ(St+1, a)
}
ϕ(St, At)
>
]∥∥∥∥∥
≤ γE
[
T−1∑
t=0
‖ϕ(St+1, a)‖
{
max
a
(
θ0
||θ − θ0|| + b
)>
ϕ(St+1, a)− max
a∈pi∗(St+1)
(
θ0
‖θ − θ0‖ + b
)>
ϕ(St+1, a)
}]
≤ γE
[
T−1∑
t=0
‖ϕ(St, At)‖
{
max
a
b>ϕ(St+1, a)− max
a∈pi∗(St+1)
b>ϕ(St+1, a)
}]
≤ γE
T−1∑
t=0
‖ϕ(St, At)‖
∑
a∈ASt+1
‖b‖‖ϕ(St+1, a)‖
 <∞.
The second inequality follows from Lemma 1 part (II) and the last inequality follows from ‖b‖ = 1 and
assumption A.5. Also, using Lemma 1 part (I), we have
lim
‖θ−θ0‖→0
[
max
a
(
θ0
||θ − θ0|| + b
)>
ϕ(St+1, a))− max
a∈pi∗(St+1)
(
θ0
‖θ − θ0‖ + b
)>
ϕ(St+1, a)
]
= 0.
We just showed that ‖D(θ)−D(θ0)− D˙θ0(θ − θ0)‖ = o(‖θ − θ0‖). Since W−1 is of full rank matrix,
[D(θ)−D(θ0)− D˙θ0(θ − θ0)]W−1[D(θ)−D(θ0)− D˙θ0(θ − θ0)]> = o(‖θ − θ0‖2).
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Now, we need to show that D˙θ0(θ − θ0)D˙θ0(θ − θ0)> ≥ c′′‖θ − θ0‖2. By definition,
D˙θ0(θ − θ0) = E
[
T−1∑
t=0
{
γ max
a∈pi∗(St+1)
(θ − θ0)>ϕ(St+1, a)− (θ − θ0)>ϕ(St, At)
}
ϕ(St, At)
>
]
= (θ − θ0)>E
[
T−1∑
t=0
{
γI|pi∗(St+1)|=1ϕ(St+1, pi
∗(St+1))− ϕ(St, At)
}
ϕ(St, At)
>
]
+ γE
[
T−1∑
t=0
{
γI|pi∗(St+1)|>1 max
a∈pi∗(St+1)
(θ − θ0)>
‖θ − θ0‖ ϕ(St+1, a)
}
ϕ(St, At)
>
]
‖θ − θ0‖.
Let
M1 = E
[
T−1∑
t=0
{
γI|pi∗(St+1)|=1ϕ(St+1, pi
∗(St+1))− ϕ(St, At)
}
ϕ(St, At)
>
]
,
M2 = E
[
T−1∑
t=0
{
I|pi∗(St+1)|>1 max
a∈pi∗(St+1)
(θ − θ0)>
‖θ − θ0‖ ϕ(St+1, a)
}
ϕ(St, At)
>
]
.
Then
D˙θ0(θ − θ0)D˙θ0(θ − θ0)> = (θ − θ0)>M1M>1 (θ − θ0) + 2γ(θ − θ0)>M1M>2 ‖θ − θ0‖+ γ2‖θ − θ0‖2M2M>2 .
Assuming that M1 is of full rank (Assumption A.7), we have
(θ − θ0)>M1M>1 (θ − θ0) ≥ ‖θ − θ0‖2λmin,
where λmin is the smallest eigenvalue of M>1 M1. Also, using singular value decomposition we have
(θ − θ0)>M1M>2 ‖θ − θ0‖ ≤ ‖θ − θ0‖2
√
λmax‖M2‖,
where λmax is a maximum eigenvalue of M1M>1 . Thus
D˙θ0(θ − θ0)D˙θ0(θ − θ0)> ≥ ‖θ − θ0‖2
[
λmin − 2γ
√
λmax‖M2‖ − γ2‖M2‖2
]
.
Therefore, function M(.) satisfies the first condition of Theorem 3.2.5 in Van Der Vaart and Wellner
(1996) for any small enough γ such that
[
λmin − 2γ
√
λmax‖M2‖ − γ2‖M2‖2
]
> 0. Note that under
assumption A.8 when |pi∗(St+1)| = 1, the latter condition is satisfied automatically. Since W is of full
rank (Assumption A.6), D˙θ0(θ − θ0)W−1D˙θ0(θ − θ0)> ≥ c‖θ − θ0‖2 for c > 0.
For the second condition, we need to show that for every large enough n, sufficiently small δn and
c > 0
E sup
‖θ−θ0‖≤δn
∣∣∣[Mˆ(θ)−M(θ)]− [Mˆ(θ0)−M(θ0)]∣∣∣ ≤ cδ2n.
Since by definition Dˆ(θˆ) = D(θ0) = 0, we have∣∣∣[Mˆ(θ)−M(θ)]− [Mˆ(θ0)−M(θ0)]∣∣∣ = ∣∣∣(Dˆ(θ)− Dˆ(θˆ))Wˆ−1(Dˆ(θ)− Dˆ(θˆ))>
− (Dˆ(θ0)− Dˆ(θˆ))Wˆ−1(Dˆ(θ0)− Dˆ(θˆ))>
−(D(θ)−D(θ0))Wˆ−1(D(θ)−D(θ0))>
∣∣∣ .
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We show that for every large n such that ‖θ − θˆ‖ ≤ δn and ‖θ0 − θˆ‖ ≤ δn
E sup
‖θ−θˆ‖≤δn
[(Dˆ(θ)− Dˆ(θˆ))Wˆ−1(Dˆ(θ)− Dˆ(θˆ))>] ≤ c1δ2n
E sup
‖θˆ−θ0‖≤δn
[(Dˆ(θ0)− Dˆ(θˆ))Wˆ−1(Dˆ(θ0)− Dˆ(θˆ))>] ≤ c2δ2n
E sup
‖θ−θ0‖≤δn
[(D(θ)−D(θ0))>Wˆ−1(D(θ)−D(θ0))>] ≤ c3δ2n,
where c1, c2 and c3 are positive constants. Here we show the first inequality and the rest can be shown sim-
ilarly. By the Cauchy-Schwartz inequality and the fact that |maxa f(a)−maxa g(a)| ≤ maxa |f(a)−
g(a)|, we have
|Dˆ(θ)− Dˆ(θˆ)| =
∣∣∣∣∣Pn
[
T−1∑
t=0
{
max
a
θ>ϕ(St+1, a)−max
a
θˆ>ϕ(St+1, a)− (θ − θˆ)>ϕ(St, At)
}
ϕ(St, At)
>
]∣∣∣∣∣
≤ Pn
[
T−1∑
t=0
‖ϕ(St, At)‖
{∑
a
‖ϕ(St+1, a)‖‖θ − θˆ‖+ ‖ϕ(St, At)‖‖θ − θˆ‖
}]
.
Thus,
|Dˆ(θ)− Dˆ(θˆ)| ≤ m(S,A)‖θ − θˆ‖,
where
m(S,A) = Pn
[
T−1∑
t=0
‖ϕ(St, At)‖
{∑
a
‖ϕ(St+1, a)‖+ ‖ϕ(St, At)‖
}]
.
Therefore
E sup
‖θ−θˆ‖≤δn
[(Dˆ(θ)− Dˆ(θˆ))>Wˆ−1(Dˆ(θ)− Dˆ(θˆ))] ≤ c1δ2n,
where c1 = E[m(S,A)2‖Wˆ−1‖]. Define c = c1 + c2 + c3. This shows that our objective function satis-
fies the second condition of Theorem 3.2.5 in Van Der Vaart and Wellner (1996) as well. This completes
the proof of consistency.
Part II (Asymptotic Normality). Let θ = θ0 + b√n and
Vˆ (b) = nDˆ(θ0 + b/
√
n)Wˆ−1Dˆ(θ0 + b/
√
n)> − nDˆ(θ0)Wˆ−1Dˆ(θ0)>.
Then,
Dˆ(θ0 + b/
√
n) = Pn
[∑
t
{
Rt+1 + γmax
a
θ>0 ϕ(St+1, a)− θ>0 ϕ(St, At)− b>/
√
nϕ(St, At)
−γmax
a
θ>0 ϕ(St+1, a) + γmax
a
(θ0 + b/
√
n)>ϕ(St+1, a)
}
ϕ(St, At)
>
]
= Pn
[∑
t
{
δt+1 − b>/
√
nϕ(St, At)− γmax
a
θ>0 ϕ(St+1, a)
+γmax
a
(θ0 + b/
√
n)>ϕ(St+1, a)
}
ϕ(St, At)
>
]
.
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Using the above equation and the defined δt+1, the function Vˆ (b) can be written as
nPn
[∑
t
{
2δt+1 − b>/
√
nϕ(St, At)− γmax
a
θ>0 ϕ(St+1, a) + γmax
a
(θ0 + b/
√
n)>ϕ(St+1, a)
}
ϕ(St, At)
>
]
Wˆ−1
×Pn
[∑
t
{
−b>/√nϕ(St, At)− γmax
a
θ>0 ϕ(St+1, a) + γmax
a
(θ0 + b/
√
n)>ϕ(St+1, a)
}
ϕ(St, At)
>
]>
.
The Vˆ (b) can be decomposed to the following parts:
I. nPn
[∑
t b
>/
√
nϕ(St, At)ϕ(St, At)
>] Wˆ−1Pn [∑t b>/√nϕ(St, At)ϕ(St, At)>]> →p b>Wb
II. nPn
[∑
t ζt+1(θ)ϕ(St, At)
>] Wˆ−1Pn [∑t ζt+1(θ)ϕ(St, At)>]> →p E [∑t ψt+1ϕ(St, At)>]W−1
×
E
[∑
t ψt+1ϕ(St, At)
>]>
III. −2nPn
[∑
t δt+1ϕ(St, At)
>] Wˆ−1Pn [∑t b>/√nϕ(St, At)ϕ(St, At)>]> →d −2Z∞b
IV. 2nPn
[∑
t δt+1ϕ(St, At)
>] Wˆ−1Pn [∑t ζt+1(θ)ϕ(St, At)>]> →d 2Z∞W−1E [∑t ψt+1ϕ(St, At)>]>
V. −2nPn
[∑
t b
>/
√
nϕ(St, At)ϕ(St, At)
>] Wˆ−1Pn [∑t ζt+1(θ)ϕ(St, At)>]> →p
−2b>E [∑t ψt+1ϕ(St, At)>]>
where ζt+1(θ) = −γmaxa θ>0 ϕ(St+1, a) + γmaxa(θ0 + b/
√
n)>ϕ(St+1, a). The first part follows
from a law of large numbers. Here, we prove Part II and the rest follow similarly.
By adding and subtracting γmaxa∈pi∗ b>/
√
nϕ(St+1, a) to ζt+1(θ), we have
ζt+1(θ) = −γ max
a∈pi∗(θ0 + b/
√
n)>ϕ(St+1, a) + γmax
a
(θ0 + b/
√
n)>ϕ(St+1, a) + γ max
a∈pi∗ b
>/
√
nϕ(St+1, a).
Thus, by Lemma 1, when ‖b/√n‖ → 0 as n→∞, we have
√
n[ζt+1(θ)]→ ψt+1,
where ψt+1 = γmaxa∈pi∗ b>ϕ(St+1, a) and by low of large numbers
√
nPn
[∑
t
ζt+1(θ)ϕ(St, At)
>
]
→p E
[∑
t
ψt+1ϕ(St, At)
>
]>
.
We just showed that Vˆ (b) converges in distribution to
V (b) = −2Z∞b+ 2Z∞W−1E
[∑
t
ψt+1ϕ(St, At)
>
]>
+ b>Wb− 2b>E
[∑
t
ψt+1ϕ(St, At)
>
]>
+ E
[∑
t
ψt+1ϕ(St, At)
>
]
W−1E
[∑
t
ψt+1ϕ(St, At)
>
]>
.
By assuming that V (b) is uniquely minimized in b and by continuity and local convexity of V (b),
√
n(θˆ − θ0) = arg min
b
Vˆ (b)→d arg min
b
V (b),
which is a consequence of the epi-convergence results of Geyer (1994). Note that when γ = 0,
arg minb V (b) = Z∞W−1. Also, under assumption A.8, that is, when |pi∗| = 1, and γ is small enough,
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arg minb V (b) = Z∞Γ, where
Γ =
[
I−γ W−1E
(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)]>
W + γ2E(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)
W−1E
(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)>
−2γE
(∑
t
ϕ(St+1, pi
∗)ϕ(St, At)>
)>−1 ,
where I is an identity matrix. Hence,
√
n(θˆ − θ0) = arg min
b
Vˆ (b)→d N(0,Γ>ΣΓ),
with Σ = E
[{∑t δt+1ϕ(St, At)>}>{∑t δt+1ϕ(St, At)>}].
S4. THE EFFECT OF THE CHOICE OF γ ON THE ESTIMATED OPTIMAL REGIME.
In this section, we have estimated the optimal treatment regime under the simulation scenario discussed
in the manuscript for different values of γ. To better reflect the effect of γ, we assume that there is no death
(i.e., Ct=0 for all t = 0, ..., 15), and the reward function is defined asr Rt = 1 if A1ct < 7, -5 if 7 < A1ct&Dt = 1 and zero otherwise.
For smaller values of γ (γ = 0.1), the estimated optimal policy will be more myopic and does not sug-
gest augmenting any medication. This happens because the side effect outweighs the treatment effect.
However, as γ gets larger, the optimal policy suggests to augment more treatments simply because the
long-term effect of treatments outweighs the side effects. This shows that γ balances the immediate and
long-term effect of treatments. Results are presented in Figure 5.
S5. THE EFFECT OF THE CHOICE OF TUNING PARAMETERS ON THE ESTIMATED OPTIMAL REGIME.
In this section, we discuss the effect of the tuning parameters (α, β) on the estimated optimal treatment
regime under the simulation scenario discussed in the manuscript. We generated 500 datasets of size 2000
and applied the proposed methods using various choices of tuning parameters:
1. α = νk log(k) and β =
ν
k for ν =0.050, 0.025, and 0.010
2. α = νk and β =
ν
k3/4
for ν =0.050, 0.025, and 0.010
3. α = νk and β =
ν
k1/3
for ν =0.050, and 0.010.
The parameter ν specifies the step size (increment size) for each choice of the tuning parameters. Figure
6 shows that as long as the step sizes are not very small, the stochastic minimization algorithm has a good
performance. However, when the step sizes are small (ν = 0.010), the algorithm fails to converge to the
true values because it cannot reach the true minimizers of the objective function. Table 1 presents the
value of the objective function at the estimated θˆ and the number of required iterations to converge (K)
using different tuning parameters. The value of the objective functionM(θ) for small ν is more than twice
the value of M(θ) for larger values of ν, which indicates the lack of convergence to the true minimizers.
Based on this result, the first choice of tuning parameter, ν = 0.05, outperforms the other choices.
Figure 7 displays the effect of tuning parameters on standard errors. The vertical axis is the ratios of the
standard errors obtained by different simulation scenarios over the standard error obtained by α = νk log(k)
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Fig. 5: Simulation: The effect of the choice of γ on the estimated optimal regime.
and β = νk and ν = 0.050. For example, the vertical axis in the first plot is
S.D. of θˆ when α = νk log(k) , β =
ν
k and ν = 0.025
S.D. of θˆ when α = νk log(k) , β =
ν
k and ν = 0.050
.
Note that the reference S.D.s in the denominator includes the tuning parameter values used in the main
simulation study in Section 4, which is shown to converge to the true values. In the first two rows, the
ratios deviate more from one as the step size (ν) gets smaller. This can be due to stoping the updates
before converging to the minimizer of the objective function.
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Fig. 6: Simulation: The effect of the choice of tuning parameters on the estimated optimal regime.
Table 1: Simulation: The effect of the choice of tuning parameters on the estimated optimal
regime.
α = 1k log(k) , β =
1
k α =
1
k , β =
1
k3/4
α = 1k , β =
1
k1/3
ν = 0.05 ν = 0.025 ν = 0.01 ν = 0.05 ν = 0.025 ν = 0.01 ν = 0.05 ν = 0.01
M(θ) 0.007 0.011 0.025 0.007 0.008 0.017 0.007 0.018
K 14.03 13.22 12.86 21.35 20.66 19.44 21.77 19.45
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